Intervention not reported
the rate of complete remission and partly remission(no special data in trial of Fu 2011) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the rate of complete remission and partly remission(no special data… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy(no special data in trial of Fu 2011, Liu 2009a, Zhang 2010) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy (very low certainty).
1 finding from 1 review
Complete remission · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F (TwHF) may leads to higher complete remission ( compared with no TwHF (low certainty).
1 finding from 1 review
Partial remission ( · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F (TwHF) showed no clear difference in partial remission ( compared with no TwHF (low certainty).
1 finding from 1 review
Complete or partial remission · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F (TwHF) may leads to higher complete or partial remission ( compared with no TwHF (low certainty).
1 finding from 1 review
Complete remission · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in complete remission ( compared with prednisone (low certainty).
1 finding from 1 review
Partial remission ( · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in partial remission ( compared with prednisone (low certainty).
1 finding from 1 review
Complete or partial remission · patients with primary nephrotic syndrome
Summary of findings: Tripterygium wilfordii Hook F showed no clear difference in complete or partial remission ( compared with prednisone (low certainty).
1 finding from 1 review
Intervention not reported
Complete remission ( · patients with primary nephrotic syndrome
The intervention showed no clear difference in complete remission ( (low certainty).
1 finding from 1 review
Intervention not reported
Partial remission ( · patients with primary nephrotic syndrome
The intervention showed no clear difference in partial remission ( (low certainty).
1 finding from 1 review
Intervention not reported
Complete or partial remission ( · patients with primary nephrotic syndrome
The intervention showed no clear difference in complete or partial remission ( (low certainty).
1 finding from 1 review
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
CHM may leads to higher total effectiveness rate (Analysis 1.1) Clinician's rating compared with placebo (low certainty).
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
CHM may leads to lower adverse events (Analysis 2.6) Participant's reports compared with drugs (low certainty).
1 finding from 1 review
Total effectiveness rate (Analysis 1.1) Clinician's rating · atopic eczema
Combination of oral and topical CHM showed no clear difference in total effectiveness rate (Analysis 3.1) Clinician's rating compared with same oral CHM (low certainty).
1 finding from 1 review
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 · atopic eczema
1 finding from 1 review
QoL · atopic eczema
1 finding from 1 review
Adverse events (Analysis 1.7) Participant's report · atopic eczema
Combination of oral and topical CHM showed no clear difference in adverse events (Analysis 3.7) Participant's report compared with same oral CHM (low certainty).
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review